Class / Patent application number | Description | Number of patent applications / Date published |
544299000 | At 2-, 4-, and 6-positions (e.g., barbituric acid, etc.) | 9 |
20080221325 | Exchange membrane containing modified maleimide oligomers - An exchange membrane containing modified maleimide oligomers comprising sulfonated poly(aryl ether ketone) (S-PAEK) and modified maleimide oligomers. The exchange membrane uses the modified maleimide oligomers having a hyper-branched architecture as matrix, and introduces them into S-PAEK to constitute semi-interpenetration network (semi-IPN), so as to intensify water holding capacity, chemical resistance, the electrochemical stability and thermal resistance of the ionic/proton exchange membrane. The exchange membrane can be used to fabricate the membrane electrode assemblies, fuel cells, and be applied them to the fields of seawater desalination, heavy water and sewage treatment, and biomass-energy resources. | 09-11-2008 |
544300000 | Additional hetero ring which is unsaturated | 3 |
20080300407 | Pyridinoylpiperidines as 5-HT1F agonists - The invention relates to compounds of formula I: | 12-04-2008 |
20120142921 | SUBSTITUTED HYDRAZIDE COMPOUNDS AND USE THEREOF - The invention relates to substituted hydrazide compounds as shown by general formula I, including geometrical isomers, pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof, and use of the same, wherein the substitutents Ar and R have the same meanings as given in the Description. The invention further relates to the use of compounds of general formula I in the preparation of medicament for the treatment and/or prevention of cancer and other proliferative diseases. | 06-07-2012 |
20130131342 | AGENT EXHIBITING THE PROPERTIES OF A COGNITIVE FUNCTION PROMOTER (EMBODIMENTS) - The present invention relates to the field of chemical-pharmaceutical industry and medicine. An agent, exhibiting the properties of a cognitive function promoter, was selected from 1,3-dimethyl-5-[(4-pyridylamino)methylene]barbituric acid and 4-amino-1-(3 -nitro-2-oxo-1-pheny-1 ,2-dihydro-1 ,6-naphthyridin-5-yl)pyridinium chloride. The compounds, that are proposed as agents, exhibit potent biological activity. | 05-23-2013 |
544301000 | Nitrogen attached directly or indirectly to the diazine ring by nonionic bonding | 3 |
20130237704 | Drug for Treating Liver Lesions Caused by the Action of Chemical or Biological Agents - The invention relates to medicine and can be used for treating liver lesions caused by chemical or biological agents. The drug for treating liver lesions caused by chemical or biological agents is embodied as 1-(4-bromophenyl)-6-hydroxy-5-nitroso-1,2,3,4-tetrahydropyrimidine-2.4-dione: (I), or salts thereof having the general formula: (II), where X is selected from Na | 09-12-2013 |
20140336383 | PROLYL HYDROXYLASE INHIBITORS - The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I) | 11-13-2014 |
20160000786 | Medicinal Drug with Activity against Gram Positive Bacteria, Mycobacteria and Fungi - The present invention discloses a nanocomposite material having single-walled aluminosilicate nanotube in polymer, a membrane comprising such nanocomposite material, and the method of making the nanocomposite material, in which the composite material has high volume fraction of well-dispersed nanotubes. A gel-phased single-walled aluminosilicate nanotube is first prepared and then mixed with a polymer matrix to yield the composite material. | 01-07-2016 |
544302000 | Additional chalcogen attached directly or indirectly to the diazine ring by nonionic bonding | 2 |
20110263854 | Improved Process For The Preparation Of Endothelin Receptor Antagonists - The present invention relates to improved processes for the preparation of Endothelin receptor antagonists, their salts and intermediates. | 10-27-2011 |
20150299140 | PREPARATION PROCESS OF CARBOXYLIC ACID DERIVATIVES AND INTERMEDIATES THEREOF - A cocrystal of (S)-2-hydroxy-3-methoxy-3,3-diphenylpropanoic acid and an amino acid, in particular L-valine or L-2-aminobutyric acid, their preparation processes, as well as the preparation process of Ambrisentan or Darusentan using any of the cocrystals of the invention. | 10-22-2015 |